J1612 Injection, glucagon (gvoke), 0.01 mg

Billable / valid for submission HCPCS Release 2026Q3

Short description: Inj glucagon (gvoke) 0.01 mg

Version history

Release	Valid from	Valid to	Description	Billable
2026Q3	2026-07-01	current	Injection, glucagon (gvoke), 0.01 mg	yes

J1600 Injection, gold sodium thiomalate, up to 50 mg
J1602 Injection, golimumab, 1 mg, for intravenous use
J1610 Injection, glucagon hydrochloride, per 1 mg
J1611 Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
J1627 Injection, granisetron, extended-release, 0.1 mg
J1628 Injection, guselkumab, 1 mg
J1630 Injection, haloperidol, up to 5 mg
J1631 Injection, haloperidol decanoate, per 50 mg
J1632 Injection, brexanolone, 1 mg
J1640 Injection, hemin, 1 mg
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units
J1643 Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units
J1644 Injection, heparin sodium, per 1000 units
J1645 Injection, dalteparin sodium, per 2500 iu
J1650 Injection, enoxaparin sodium, 10 mg
J1652 Injection, fondaparinux sodium, 0.5 mg
J1670 Injection, tetanus immune globulin, human, up to 250 units
J1675 Injection, histrelin acetate, 10 micrograms